Zynerba Pharmaceuticals
$11.909876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$11.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.03 (-0.25%) Today
$0.00 (0.00%) As of 4:15 PM EDT after-hours
Why Robinhood?
You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!
About ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
276.06M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
838.57K
High Today
$12.51
Low Today
$11.56
Open Price
$11.99
Volume
992.34K
52 Week High
$16.47
52 Week Low
$2.75
Collections
Price Paid on Robinhood
55% Higher
Right Now
52 Week Low
$2.75
Average Price Paid
$7.66
52 Week High
$12.50
Analyst Ratings
83%
of 6 ratings
Buy
83%
Hold
17%
Sell
0%
ZYNE Earnings
-$0.91
-$0.75
-$0.60
-$0.44
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected Nov 7, Pre-Market